In this study, we investigated the anticancer efficacy of pyrotinib in combination with chrysin as a novel therapeutic regimen and explored the underlying molecular mechanisms in the treatment of HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.